Cardinal Health Inc

Latest Cardinal Health Inc News and Updates

  • cah stock buy or sell
    Analyst Price Target

    Is Cardinal Health Stock a Buy or Sell at the Current Prices?

    Is CAH stock a buy after its underperformance or are investors better off selling the stock given its perennial underperformance?
    By Mohit Oberoi, CFA
  • uploads///US Investment Grade Bond Fund Flows
    Company & Industry Overviews

    Investment-Grade Bond Funds Saw Outflows Last Week

    Flows into investment-grade bond funds (LQD) were negative in the week ending June 17. This was the second consecutive week witnessing outflows.

    By David Ashworth
  • uploads///US Investment Grade Bond Market Issuance
    Company & Industry Overviews

    Issuance of Investment-Grade Corporate Bonds Fell Last Week

    Baxalta, Energy Transfer Partners, JPMorgan Chase, Occidental Petroleum, and Cardinal Health were among the biggest issuers of investment-grade corporate bonds last week.

    By David Ashworth
  • uploads///GILD
    Company & Industry Overviews

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.

    By Kenneth Smith
  • uploads///thermometer _
    Company & Industry Overviews

    How GlaxoSmithKline Stock Has Performed in September

    Analyst estimates suggest GlaxoSmithKline stock could rise ~6.3% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Earnings Quality and Dividend Performance

    Pfizer’s dividend yield is 3.09%. Its dividend yield last year was 3.53%, and its five-year average yield is 3.44%.

    By Mike Benson
  • uploads///us pharmacies
    Company & Industry Overviews

    How Pharmacies and Drugstores Are Defending against Amazon

    Amazon’s (AMZN) purchase of PillPack is expected to pose a threat to existing players in the pharmaceutical space.

    By Anne Shields
  • uploads///DEPO
    Company & Industry Overviews

    Behind Depomed’s Business Strategy

    Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow.

    By Kenneth Smith
  • uploads///doctors office checkup medical
    Company & Industry Overviews

    Analysts’ Ratings for AmerisourceBergen in March 2018

    Four analysts gave AmerisourceBergen stock a “strong buy” rating, seven analysts gave it a “buy” rating, and seven analysts gave it a “hold” rating.

    By Kenneth Smith
  • uploads///ABC
    Company & Industry Overviews

    Analyzing AmerisourceBergen’s Recent Acquisitions

    In December 2017, AmerisourceBergen (ABC) acquired Northeast Supply Company, or NEVSCO, for a consideration of $70 million.

    By Kenneth Smith
  • uploads///STOCK PRICE
    Company & Industry Overviews

    Discussing Baxter International’s Recent Stock Price Highs

    On January 4, 2018, Baxter International was trading at a 52-week high of $68.86 per share, ending the day at $68.41 per share.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Patient Recovery Acquisition May Boost Cardinal Health’s Revenues

    On July 30, 2017, Cardinal Health (CAH) completed the acquisition of Medtronic’s patient recovery business for an all-cash consideration worth $6.1 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Robust Growth Expected for Cardinal Health’s Specialty Solutions

    Cardinal Health’s (CAH) Specialty Solutions segment provides two types of services: upstream to pharmaceutical and biopharmaceutical manufacturers and downstream to healthcare providers.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cardinal Health: Stable Net Profit Margins in Fiscal 2018?

    Wall Street analysts have projected Cardinal Health’s fiscal 2018 net profit margins to be 1.0%, which will be similar to what the company reported in fiscal 2017.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Cardinal Health Expected to Report Modest Revenue Growth

    For fiscal 2018, Cardinal Health (CAH) has projected mid-single-digit revenue growth on a YoY basis, partially driven by the company’s high customer retention rates.

    By Margaret Patrick
  • uploads///new MITG structure
    Company & Industry Overviews

    Divestiture of a Part of Medtronic’s PMR Business to Cardinal Health

    Medtronics’ MITG (Minimally Invasive Therapies Group) business is expected to grow 3.5%–4.5%.

    By Sarah Collins
  • uploads///DY CAH
    Healthcare

    Dividend Yield of Cardinal Health

    Cardinal Health’s (CAH) PE ratio of 16.0x compares to a sector average of 20.4x. The dividend yield of 2.9% compares to a sector average of 2.0%.

    By Amanda Lawrence
  • uploads///cardinal health
    Company & Industry Overviews

    Medtronic Will Divest Part of Its PMR Business to Cardinal Health

    On April 18, Medtronic announced the divestiture of its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal Health.

    By Sarah Collins
  • uploads/uploads///Vanguard Morgan Growth Fund %E%% Investor Shares Vs Peers
    Company & Industry Overviews

    An Above-Average One-Year Period for Vanguard Morgan Growth Fund

    The Vanguard Morgan Growth Fund – Investor Shares (VMRGX) is invested in stocks of companies like Nike (NKE), Netflix (NFLX), The Walt Disney Company (DIS), Cardinal Health (CAH), and Vantiv (VNTV).

    By David Ashworth
  • uploads///Part  Graph
    Company & Industry Overviews

    How Have XLV’s Large-Caps Performed?

    XLV has 49 large-cap stocks in its holdings, with a combined market cap of more than $10 billion. Among them, 47 stocks fell on March 15, 2016.

    By Peter Neil
  • uploads///
    Company & Industry Overviews

    A Look at Walgreens Boots’ Pharmaceutical Wholesale Division

    Walgreens Boots Alliance’s (WBA) Pharmaceutical Wholesale division consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses.

    By Sonya Bells
  • uploads///
    Company & Industry Overviews

    Walgreens Boots Alliance: Merger of Walgreens and Alliance Boots

    Walgreens became a wholly owned subsidiary of Walgreens Boots Alliance after a merger.

    By Sonya Bells
  • uploads///hsic pm
    Company & Industry Overviews

    Henry Schein Acquired RxWorks and Greggs Increased Sales

    Henry Schein reported 3Q15 net sales of $2,685.8 million, a rise of 2.4% compared to the net sales of $2,623.7 million in fiscal 3Q14.

    By Gabriel Kane
  • uploads///MEDICAL SPENDING V
    Company & Industry Overviews

    Analyzing Cost Structure for Medical Device Companies

    As per the US Census, spending on medical devices in the US has been constant for over a decade between 2005 to 2015.

    By Sarah Collins
  • uploads///marketing and sales
    Company & Industry Overviews

    Assessing Medtronic’s Marketing and Sales Strategy in 2015

    To extend cost-effective, high-quality medical devices and therapies, Medtronic aims to organize its marketing and sales teams around physician preferences.

    By Sarah Collins
  • uploads///Performances of Oil Gold Bond and the US Dollar versus SPY
    Macroeconomic Analysis

    China’s November 2015 PMI Pressured Oil Prices, US Market Bullish

    US investors seemed to take the weak Chinese manufacturing data released by Caixin in stride on November 2. China’s PMI rose from September’s reading of 47.2 to 48.3 for October 2015.

    By Renee Blakely
  • uploads///Part
    Earnings Report

    Drivers That Impact CVS’s Pharmacy Services Segment

    CVS Health (CVS) is projecting 2Q15 revenue growth between 11.25% and 12.5% for its Pharmacy Services, which provides pharmacy benefit management (or PBM) services.

    By Phalguni Soni
  • uploads///Part
    Miscellaneous

    How CVS Plans to Make Target’s Pharmacies Profitable

    CVS is planning to transfer Target’s generic business to Red Oak Sourcing. Target currently sources from McKesson.

    By Phalguni Soni
  • uploads///Cash Reserve
    Earnings Report

    Does Johnson & Johnson Have a Plan for Huge Cash Reserve?

    Johnson & Johnson (JNJ) has a huge cash reserve amounting to ~$15 billion in 4Q14. The company might use the cash for merger and acquisition (or M&A).

    By Nicole Sario
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.